Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Gensight Biologics SA
G49NGenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France. Address: 74, rue du Faubourg Saint-Antoine, Paris, France, 75012
Analytics
Preço Alvo de Wall Street
0.37 EURRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave G49N
Análise de Dividendos G49N
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos G49N
Avaliação de ações G49N
Relatório G49N
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |